105858.jpg
Tomorrow I've pharmacology practical exam and the topic is P drug. Answer the above question in following category: 1. P group 2. P drug And each category should have following सब categories: 1. Drug 2. Safety 3. Efficiency 3. Suitability 4. Cost Also mention the dose and frequency of the P drug MBBS PHARMACOLOGY 2ND YEAR
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Here is the complete P Drug practical answer guide for all 18 topics from your image. The format used is standard MBBS 2nd year pharmacology practical P drug format.
P DRUG PRACTICAL - COMPLETE ANSWER GUIDE
MBBS 2nd Year Pharmacology
What is P Drug? A "Personal Drug" (P Drug) is the drug you choose as your drug of first choice for a given condition, based on Efficacy, Safety, Suitability, and Cost (ESSC criteria).
1. VERTIGO
| Category | Details |
|---|---|
| P Group | Antihistaminics (H1 blockers with vestibular suppressant action) |
| P Drug | Cinnarizine |
| Drug | Cinnarizine - acts on H1 receptors and also has Ca2+ channel blocking activity on vestibular system |
| Efficacy | Effective in reducing vertigo, nausea, and vomiting; acts on both central and peripheral vestibular system |
| Safety | Well tolerated; may cause drowsiness, dry mouth; avoid in Parkinson's disease |
| Suitability | Suitable for most adults including elderly; oral administration; avoid in pregnancy |
| Cost | Inexpensive, widely available |
| Dose & Frequency | 25 mg TDS (three times a day) orally |
2. ACUTE ATTACK OF MILD MIGRAINE
| Category | Details |
|---|---|
| P Group | NSAIDs / Mild analgesics |
| P Drug | Aspirin (or Ibuprofen) |
| Drug | Aspirin - inhibits COX-1 and COX-2, reduces prostaglandin synthesis; also inhibits platelet aggregation |
| Efficacy | Effective for mild-to-moderate migraine attacks; reduces headache, nausea |
| Safety | Avoid in peptic ulcer disease, bleeding disorders, children <16 yrs (Reye's syndrome); avoid in asthmatics |
| Suitability | Suitable for adults without contraindications; can be combined with metoclopramide for better absorption |
| Cost | Very cheap, widely available |
| Dose & Frequency | 600-900 mg as a single dose at onset of attack; can repeat after 4-6 hrs; max 4g/day |
3. ACUTE ATTACK OF SEVERE MIGRAINE
| Category | Details |
|---|---|
| P Group | 5-HT1B/1D receptor agonists (Triptans) |
| P Drug | Sumatriptan |
| Drug | Sumatriptan - selective 5-HT1B/1D agonist; causes cranial vasoconstriction, inhibits neuropeptide release, reduces neurogenic inflammation |
| Efficacy | Gold standard for acute severe migraine; relieves headache, nausea, photophobia within 1-2 hrs; most effective antimigraine drug |
| Safety | Contraindicated in IHD, uncontrolled hypertension, hemiplegic/basilar migraine, pregnancy; may cause chest tightness, flushing, paresthesia ("triptan sensations") |
| Suitability | Suitable for adults with severe migraine not responding to NSAIDs; not for prophylaxis |
| Cost | Expensive compared to NSAIDs but cost-effective for severe attacks |
| Dose & Frequency | 50-100 mg oral at onset; may repeat after 2 hrs if needed; max 300 mg/day. SC: 6 mg subcutaneously; Nasal spray: 10-20 mg |
4. ACUTE CONGESTIVE GLAUCOMA
| Category | Details |
|---|---|
| P Group | Osmotic diuretics + Carbonic anhydrase inhibitors |
| P Drug | Acetazolamide (systemic) + Pilocarpine (topical) |
| Drug | Acetazolamide - carbonic anhydrase inhibitor; reduces aqueous humor production. Pilocarpine - direct muscarinic agonist; opens trabecular meshwork by pupillary constriction |
| Efficacy | Rapidly lowers IOP in acute angle closure; Pilocarpine opens drainage angle |
| Safety | Acetazolamide: avoid in sulfa allergy, hepatic/renal failure; may cause metabolic acidosis, hypokalemia. Pilocarpine: may cause spasm of accommodation, brow ache |
| Suitability | Emergency use; once pupil responds to pilocarpine, definitive surgery (iridotomy) is the cure |
| Cost | Moderate; both available widely |
| Dose & Frequency | Acetazolamide: 500 mg IV immediately, then 250 mg orally QID. Pilocarpine: 2% eye drops - 1 drop every 15 min for 1 hour, then every 6 hrs |
5. OPEN ANGLE GLAUCOMA
| Category | Details |
|---|---|
| P Group | Prostaglandin analogs (topical) |
| P Drug | Latanoprost |
| Drug | Latanoprost - FP prostaglandin receptor agonist; increases uveoscleral outflow of aqueous humor |
| Efficacy | Most effective single agent for reducing IOP (reduces by 25-35%); once daily dosing enhances compliance |
| Safety | Local side effects: iris pigmentation, eyelash growth (hypertrichosis), conjunctival hyperemia; avoid in uveitic glaucoma |
| Suitability | First-line for open angle glaucoma; once-nightly dosing; suitable for most patients |
| Cost | Moderately expensive but cost-effective due to once-daily dosing |
| Dose & Frequency | 0.005% eye drops, 1 drop once daily at bedtime |
Alternative P Drug: Timolol 0.5% - beta blocker, 1 drop BD, cheaper but contraindicated in asthma/COPD/heart block
6. ANAPHYLACTIC SHOCK
| Category | Details |
|---|---|
| P Group | Sympathomimetic amines / Catecholamines |
| P Drug | Adrenaline (Epinephrine) |
| Drug | Epinephrine - acts on α1 (vasoconstriction, raises BP), β1 (increases HR and contractility), β2 (bronchodilation); physiologic antagonist of anaphylaxis mediators |
| Efficacy | ONLY life-saving drug in anaphylaxis; reverses all features - bronchospasm, hypotension, urticaria, angioedema; acts within minutes |
| Safety | May cause palpitations, arrhythmias, hypertensive crisis; use cautiously in elderly/cardiac patients; but benefits always outweigh risks in anaphylaxis |
| Suitability | IM route preferred (anterolateral thigh); suitable for all ages including children; no absolute contraindication in anaphylaxis |
| Cost | Very cheap, universally available |
| Dose & Frequency | 0.5 mg (0.5 mL of 1:1000) IM in anterolateral thigh; repeat every 5-15 min as needed. Children: 0.01 mg/kg |
7. UNCOMPLICATED FALCIPARUM MALARIA
| Category | Details |
|---|---|
| P Group | Artemisinin-based Combination Therapy (ACT) |
| P Drug | Artemether + Lumefantrine (Coartem) |
| Drug | Artemether - rapidly acting blood schizonticide, acts on all stages; Lumefantrine - partner drug prevents recrudescence; combination prevents resistance |
| Efficacy | WHO first-line for uncomplicated P. falciparum; cure rate >95%; works even against chloroquine-resistant strains |
| Safety | Generally well tolerated; may cause nausea, dizziness, QT prolongation (mild); avoid in 1st trimester of pregnancy |
| Suitability | Oral formulation; suitable for adults and children; take with fatty food to enhance absorption |
| Cost | Moderately expensive; available free/subsidized through NVBDCP in India |
| Dose & Frequency | Artemether 20mg + Lumefantrine 120mg - 4 tablets at 0, 8, 24, 36, 48, 60 hours (6 doses total for adults >35 kg) |
Note: In India, ACT (Artesunate + SP + Primaquine) is the national program drug for Pf malaria
8. SHIGELLOSIS (Acute Bacterial Dysentery)
| Category | Details |
|---|---|
| P Group | Fluoroquinolones |
| P Drug | Ciprofloxacin |
| Drug | Ciprofloxacin - inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV; bactericidal against gram-negative organisms including Shigella |
| Efficacy | Drug of choice for Shigellosis; shortens illness duration, reduces transmission; highly effective against Shigella spp. |
| Safety | Avoid in children <12 yrs (cartilage toxicity), pregnancy, tendon disorders; may cause GI upset, photosensitivity, QT prolongation |
| Suitability | Oral route; short course (3-5 days) effective; ORS must accompany antibiotics |
| Cost | Inexpensive, widely available as generic |
| Dose & Frequency | 500 mg BD (twice daily) for 3-5 days |
9. TYPHOID FEVER
| Category | Details |
|---|---|
| P Group | Fluoroquinolones |
| P Drug | Ciprofloxacin |
| Drug | Ciprofloxacin - bactericidal against Salmonella typhi; achieves high intracellular concentration within macrophages where the bacteria reside |
| Efficacy | Highly effective; defervescence in 3-5 days; low relapse rate; short course treatment possible |
| Safety | Same as above; avoid in children, pregnancy |
| Suitability | Oral administration; 7-10 day course standard |
| Cost | Very cheap as generic |
| Dose & Frequency | 500 mg BD (twice daily) for 7-10 days |
Alternative: Azithromycin 1g on day 1, then 500mg OD for 6 days (preferred in pregnancy and children)
10. PULMONARY EDEMA DUE TO LEFT-SIDED CHF
| Category | Details |
|---|---|
| P Group | Loop diuretics |
| P Drug | Furosemide (Frusemide) |
| Drug | Furosemide - inhibits Na+/K+/2Cl- cotransporter in thick ascending limb of Loop of Henle; causes massive diuresis; also has early venodilatory effect (within 5 min of IV) that reduces preload before diuresis begins |
| Efficacy | Most powerful diuretic; most effective drug for acute pulmonary edema; dual mechanism (early venodilation + later diuresis); reduces dyspnea rapidly |
| Safety | May cause hypokalemia, hyponatremia, ototoxicity (with high doses), hyperuricemia, hyperglycemia; not safe in anuria |
| Suitability | IV route in acute setting; suitable for all adults; monitor electrolytes and urine output |
| Cost | Very cheap, universally available |
| Dose & Frequency | Acute pulmonary edema: 40 mg IV slow injection; may repeat with 80 mg if inadequate response. Maintenance: 20-80 mg OD orally |
11. HYPERTENSION IN PREGNANT WOMAN (PREECLAMPSIA)
| Category | Details |
|---|---|
| P Group | Centrally acting alpha-2 agonists / Vasodilators |
| P Drug | Methyldopa |
| Drug | Methyldopa - converted to alpha-methylnorepinephrine in CNS; acts on central α2 receptors to reduce sympathetic outflow; reduces peripheral vascular resistance |
| Efficacy | Effective antihypertensive; proven long-term safety record for fetus and mother in pregnancy; most studied drug in obstetric hypertension |
| Safety | SAFE in pregnancy (Category B); fetal safety well documented. May cause sedation, dry mouth, hemolytic anemia, positive Coombs test, hepatotoxicity |
| Suitability | Drug of CHOICE for chronic hypertension in pregnancy; for acute severe hypertension in preeclampsia, IV labetalol or hydralazine is used |
| Cost | Cheap, widely available |
| Dose & Frequency | 250 mg BD-TDS initially; usual maintenance 500 mg - 2g/day in divided doses |
For acute severe HTN in preeclampsia (BP >160/110): IV Labetalol or IV Hydralazine 5 mg IV bolus
12. STABLE ANGINA
| Category | Details |
|---|---|
| P Group | Beta-adrenergic blockers |
| P Drug | Atenolol |
| Drug | Atenolol - selective β1 blocker; reduces heart rate, myocardial contractility, and oxygen demand; increases diastolic filling time (improves coronary perfusion) |
| Efficacy | Reduces frequency and severity of angina attacks; reduces mortality post-MI; prevents exercise-induced angina; no tolerance develops |
| Safety | Contraindicated in asthma/COPD, bradycardia, heart block, decompensated heart failure; may cause fatigue, cold extremities, mask hypoglycemia |
| Suitability | First-line for stable angina; once or twice daily dosing; especially preferred in patients with hypertension, post-MI, tachycardia |
| Cost | Very cheap, widely available |
| Dose & Frequency | 25-100 mg OD (once daily) |
For acute attack of angina: Sublingual glyceryl trinitrate (GTN) 0.5 mg stat
13. PARKINSONISM
| Category | Details |
|---|---|
| P Group | Dopamine precursor + Decarboxylase inhibitor |
| P Drug | Levodopa + Carbidopa (Co-careldopa) |
| Drug | Levodopa - converted to dopamine in CNS; replenishes depleted striatal dopamine. Carbidopa - peripheral DOPA decarboxylase inhibitor; prevents peripheral conversion of levodopa, reducing side effects and increasing CNS availability |
| Efficacy | Most effective drug for Parkinsonism; best symptomatic relief of tremor, rigidity, bradykinesia; gold standard |
| Safety | May cause nausea, vomiting, dyskinesias, on-off phenomenon, psychosis; avoid in narrow angle glaucoma, psychosis. Long-term use causes wearing-off and peak-dose dyskinesias |
| Suitability | For patients with significant functional impairment; start low, go slow; not suitable as first-line in young patients (<60 yrs) - prefer dopamine agonists (pramipexole) to delay levodopa |
| Cost | Moderately priced; available as generic |
| Dose & Frequency | Initially Carbidopa 25mg + Levodopa 100mg (Syndopa-Plus) TDS; titrate up slowly; usual maintenance up to 200/800 mg per day in divided doses |
14. OSTEOPOROSIS
| Category | Details |
|---|---|
| P Group | Bisphosphonates |
| P Drug | Alendronate (Alendronic acid) |
| Drug | Alendronate - inhibits osteoclast-mediated bone resorption by incorporating into bone matrix and disrupting osteoclast farnesyl pyrophosphate synthase; antiresorptive |
| Efficacy | Reduces vertebral and hip fracture risk by ~50%; increases bone mineral density (BMD); best evidence base among all anti-osteoporosis drugs |
| Safety | GI irritation, esophageal ulceration (must take with full glass of water, remain upright for 30 min); osteonecrosis of jaw (rare, with long-term use); atrial fibrillation; atypical femoral fractures |
| Suitability | First-line for postmenopausal osteoporosis and steroid-induced osteoporosis; weekly dosing improves compliance; must be given with calcium + Vit D supplementation |
| Cost | Cheap (generic available); weekly formulation reduces cost |
| Dose & Frequency | 70 mg once weekly orally (morning, fasting, with plain water only, sit upright 30 min) |
15. OSTEOARTHRITIS OF BOTH KNEES
| Category | Details |
|---|---|
| P Group | Analgesics (non-opioid) |
| P Drug | Paracetamol (Acetaminophen) |
| Drug | Paracetamol - inhibits COX enzymes in CNS (central action); also activates descending serotonergic pathways; analgesic and antipyretic, NO anti-inflammatory action |
| Efficacy | Effective for mild-moderate OA pain; first-line analgesic per ACR/EULAR guidelines for OA |
| Safety | SAFEST analgesic; no GI ulceration, no platelet inhibition, no renal prostaglandin inhibition; hepatotoxic only in overdose (>4g/day) or with alcohol |
| Suitability | Suitable for elderly, those with peptic ulcer, renal impairment, cardiac disease; preferred over NSAIDs in OA |
| Cost | Extremely cheap, universally available |
| Dose & Frequency | 500 mg - 1g TDS to QID (up to 4g/day maximum); regular scheduled dosing better than PRN |
16. ACUTE GOUTY ARTHRITIS
| Category | Details |
|---|---|
| P Group | NSAIDs (for acute attack) |
| P Drug | Indomethacin |
| Drug | Indomethacin - potent non-selective COX inhibitor; reduces prostaglandin synthesis; also inhibits urate crystal phagocytosis and neutrophil migration into joint |
| Efficacy | Most effective NSAID for acute gout; rapid relief of inflammation and pain within 24-48 hrs; drug of choice for acute gouty attack |
| Safety | GI irritation (take with food), peptic ulceration, fluid retention, renal impairment; avoid in renal failure, peptic ulcer, elderly |
| Suitability | Short course (5-7 days) during acute attack only; not for chronic use; combine with PPI for GI protection |
| Cost | Cheap, widely available |
| Dose & Frequency | 50 mg TDS for 2-3 days, then taper; or 75 mg BD for 5-7 days |
Alternative for gout: Colchicine 0.5-1 mg BD for 5 days (preferred in elderly/cardiac patients who can't tolerate NSAIDs)
17. RHEUMATOID ARTHRITIS
| Category | Details |
|---|---|
| P Group | Disease Modifying Anti-Rheumatic Drugs (DMARDs) |
| P Drug | Methotrexate (MTX) |
| Drug | Methotrexate - folate antagonist; inhibits DHFR (dihydrofolate reductase); reduces lymphocyte proliferation and inflammatory cytokine production; immunosuppressive and anti-inflammatory |
| Efficacy | Anchor drug / gold standard DMARD for RA; slows disease progression, reduces erosions, improves function; most widely used DMARD worldwide |
| Safety | Hepatotoxicity, bone marrow suppression, pulmonary toxicity (MTX pneumonitis), teratogenicity, mucositis; must give folic acid supplementation 5mg/day to reduce side effects; regular LFT and CBC monitoring |
| Suitability | Weekly dosing improves compliance; must avoid alcohol; contraindicated in pregnancy (Category X), significant renal/hepatic disease; use effective contraception |
| Cost | Very cheap, widely available |
| Dose & Frequency | 7.5-25 mg once weekly (oral or SC/IM); start with 7.5-10 mg/week, increase by 2.5 mg every 4-6 weeks |
18. TYPE 2 DIABETES MELLITUS (Maturity Onset Diabetes)
| Category | Details |
|---|---|
| P Group | Biguanides |
| P Drug | Metformin |
| Drug | Metformin - activates AMP-activated protein kinase (AMPK); primarily reduces hepatic gluconeogenesis; also improves peripheral insulin sensitivity; does NOT cause hypoglycemia |
| Efficacy | First-line drug for T2DM per all major guidelines (ADA, IDF); reduces HbA1c by 1-2%; also has cardiovascular protective effects (UKPDS); no weight gain |
| Safety | GI side effects (nausea, diarrhea) - mitigated by taking with food; most serious risk: lactic acidosis (rare); contraindicated in renal impairment (eGFR <30), liver disease, heart failure, alcoholism; hold before contrast |
| Suitability | Drug of choice for T2DM, especially overweight/obese patients; no hypoglycemia; cardioprotective; cheap; suitable for most patients |
| Cost | Very cheap, generic widely available |
| Dose & Frequency | 500 mg OD or BD with meals initially; titrate up to 1000 mg BD (max 2.5g/day); Extended release: 500-2000 mg OD at dinner |
QUICK REFERENCE SUMMARY TABLE
| # | Condition | P Group | P Drug | Dose |
|---|---|---|---|---|
| 1 | Vertigo | Antihistaminics | Cinnarizine | 25 mg TDS |
| 2 | Mild Migraine | NSAIDs | Aspirin | 600-900 mg stat |
| 3 | Severe Migraine | Triptans | Sumatriptan | 50-100 mg stat |
| 4 | Acute Glaucoma | CA inhibitor + Miotic | Acetazolamide + Pilocarpine | 500 mg IV + 2% drops |
| 5 | Open Angle Glaucoma | Prostaglandin analog | Latanoprost | 0.005% 1 drop OD HS |
| 6 | Anaphylaxis | Sympathomimetic | Adrenaline | 0.5 mg IM (1:1000) |
| 7 | Falciparum Malaria | ACT | Artemether-Lumefantrine | 4 tabs x 6 doses |
| 8 | Shigellosis | Fluoroquinolone | Ciprofloxacin | 500 mg BD x 3-5 days |
| 9 | Typhoid | Fluoroquinolone | Ciprofloxacin | 500 mg BD x 7-10 days |
| 10 | Pulmonary Edema | Loop diuretic | Furosemide | 40-80 mg IV |
| 11 | HTN in Pregnancy | Alpha-2 agonist | Methyldopa | 250 mg BD-TDS |
| 12 | Stable Angina | Beta-blocker | Atenolol | 25-100 mg OD |
| 13 | Parkinsonism | Levodopa + DCI | Levodopa + Carbidopa | 100/25 mg TDS |
| 14 | Osteoporosis | Bisphosphonate | Alendronate | 70 mg once weekly |
| 15 | Osteoarthritis | Analgesic | Paracetamol | 500 mg-1g TDS-QID |
| 16 | Acute Gout | NSAID | Indomethacin | 50 mg TDS x 5-7 days |
| 17 | Rheumatoid Arthritis | DMARD | Methotrexate | 7.5-25 mg once weekly |
| 18 | Type 2 DM | Biguanide | Metformin | 500-1000 mg BD |
Key Exam Tips:
- Always justify your P drug choice using ESSC criteria (Efficacy, Safety, Suitability, Cost)
- Mention at least one important contraindication and one side effect for Safety
- For Suitability - mention route of administration and any special population consideration
- For acute conditions (Anaphylaxis, Pulmonary Edema, Acute Glaucoma) - emphasize speed of action
Good luck in your practical tomorrow! 🎯
Do it in a tabular method. Also mention all the p groups possible then select the best group. Then mention all drugs in that group and then select the best p drug out of it. In safety also mention adverse reaction of drugs
Here is the complete P Drug practical guide in full tabular format for all 18 conditions:
P DRUG PRACTICAL - COMPLETE TABULAR FORMAT
MBBS 2nd Year Pharmacology
1. VERTIGO
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Antihistaminics (H1 blockers) ✅ SELECTED | Vestibular suppressant + antiemetic; most effective for vertigo |
| 2 | Anticholinergics (Scopolamine) | Effective but more side effects (dry mouth, blurred vision, confusion in elderly) |
| 3 | Benzodiazepines (Diazepam) | Sedation, dependence risk; reserved for severe/refractory cases |
| 4 | Dopamine antagonists (Metoclopramide) | Mainly antiemetic; less specific for vestibular suppression |
P DRUG SELECTION
| # | Drugs in P Group (Antihistaminics) | Reason to Select / Reject |
|---|---|---|
| 1 | Cinnarizine ✅ SELECTED | H1 blocker + Ca2+ channel blocker on vestibular system; dual action, best profile |
| 2 | Promethazine | Effective but more sedating; anticholinergic side effects |
| 3 | Meclizine | Good but less available in India; OD dosing but weaker vestibular action |
| 4 | Diphenhydramine | Strong sedation; short duration of action |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Antihistaminics (H1 blockers) |
| P Drug | Cinnarizine |
| Drug (Mechanism) | H1 receptor blocker + calcium channel blocker; suppresses vestibular nucleus excitability and reduces endolymph pressure |
| Efficacy | Effective for peripheral and central vertigo; reduces nausea, vomiting, and dizziness; dual mechanism gives advantage |
| Safety | Generally safe. Adverse Reactions: Drowsiness, sedation, dry mouth, weight gain, extrapyramidal symptoms (with long-term use), depression; avoid in Parkinson's disease |
| Suitability | Oral route; suitable for adults and elderly; avoid in pregnancy (1st trimester); caution in Parkinson's |
| Cost | Cheap, widely available as generic |
| Dose & Frequency | 25 mg TDS orally |
2. ACUTE ATTACK OF MILD MIGRAINE
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | NSAIDs / Simple Analgesics ✅ SELECTED | First-line for mild attacks; effective, cheap, widely available |
| 2 | Triptans (5-HT1B/D agonists) | Reserved for moderate-severe migraine; expensive; overkill for mild attacks |
| 3 | Ergot alkaloids | Significant vasoconstrictor side effects; second-line |
| 4 | Antiemetics (Metoclopramide) | Used adjunctively, not primary treatment |
| 5 | Opioids | Dependence risk; not recommended for migraine |
P DRUG SELECTION
| # | Drugs in P Group (NSAIDs/Analgesics) | Reason to Select / Reject |
|---|---|---|
| 1 | Aspirin ✅ SELECTED | Cheap, effective, also has antiplatelet benefit; well studied in migraine |
| 2 | Ibuprofen | Also effective; alternative P drug but narrower GI safety window |
| 3 | Naproxen | Longer acting but slower onset |
| 4 | Paracetamol | Weaker efficacy in migraine; lacks anti-inflammatory action |
| 5 | Diclofenac | Effective but more GI and CV risk |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | NSAIDs (Non-Selective COX inhibitors) |
| P Drug | Aspirin |
| Drug (Mechanism) | Irreversibly inhibits COX-1 and COX-2; reduces prostaglandin and thromboxane synthesis; also has antiplatelet and mild anti-inflammatory action |
| Efficacy | Effective for mild-moderate migraine; can be combined with metoclopramide (10 mg) to enhance absorption and add antiemetic effect |
| Safety | Adverse Reactions: GI irritation, peptic ulceration, GI bleeding, hypersensitivity (aspirin-sensitive asthma), Reye's syndrome (children <16 yrs), tinnitus at high doses, platelet inhibition leading to bleeding |
| Suitability | Oral route; avoid in peptic ulcer, bleeding disorders, children, aspirin-sensitive asthma, 3rd trimester pregnancy |
| Cost | Extremely cheap |
| Dose & Frequency | 600-900 mg as single dose at onset; repeat after 4-6 hrs if needed; max 4g/day |
3. ACUTE ATTACK OF SEVERE MIGRAINE
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | 5-HT1B/1D Receptor Agonists (Triptans) ✅ SELECTED | Most effective, migraine-specific; gold standard for severe attacks |
| 2 | NSAIDs | Insufficient for severe migraine |
| 3 | Ergot alkaloids (Ergotamine) | Effective but non-selective vasoconstrictor; more dangerous side effects; triptans are superior |
| 4 | Opioids | Dependence, not recommended; may worsen nausea |
| 5 | Antiemetics alone | Insufficient as monotherapy for severe headache |
P DRUG SELECTION
| # | Drugs in P Group (Triptans) | Reason to Select / Reject |
|---|---|---|
| 1 | Sumatriptan ✅ SELECTED | First triptan; most evidence; multiple routes (oral/SC/nasal); benchmark drug |
| 2 | Rizatriptan | Faster onset; oral; alternative but less data than sumatriptan |
| 3 | Eletriptan | Good CNS penetration; higher efficacy but more expensive |
| 4 | Naratriptan | Slower onset; better tolerated; for patients with side effects to sumatriptan |
| 5 | Frovatriptan | Longest half-life (26 hrs); preferred for menstrual migraine |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | 5-HT1B/1D Receptor Agonists (Triptans) |
| P Drug | Sumatriptan |
| Drug (Mechanism) | Selective 5-HT1B/1D agonist → cranial vasoconstriction, inhibits trigeminal neuropeptide (CGRP, substance P) release, blocks central pain transmission |
| Efficacy | Gold standard for acute severe migraine; relieves headache in 70-80% within 2 hrs; also relieves nausea, photophobia, phonophobia; available in oral, SC, nasal spray forms |
| Safety | Adverse Reactions: "Triptan sensations" - chest tightness/pressure, flushing, paresthesia of neck/jaw/chest; nausea, dizziness, somnolence; coronary vasospasm (rare). Contraindicated: IHD, uncontrolled HTN, hemiplegic/basilar migraine, pregnancy, within 24 hrs of ergotamine |
| Suitability | Adults with moderate-severe migraine; not for prophylaxis; SC route useful when vomiting prevents oral intake |
| Cost | Moderately expensive but cost-effective for severe disabling attacks |
| Dose & Frequency | Oral: 50-100 mg stat; repeat after 2 hrs if needed; max 300 mg/day. SC: 6 mg subcutaneously. Nasal: 10-20 mg |
4. ACUTE CONGESTIVE (ANGLE CLOSURE) GLAUCOMA
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Carbonic Anhydrase Inhibitors (systemic) ✅ SELECTED | Rapidly reduces aqueous humor production; IV route for emergency |
| 2 | Osmotic agents (Mannitol) | Also rapidly reduces IOP; used if CA inhibitor inadequate |
| 3 | Miotics (Pilocarpine - topical) | Opens drainage angle; used alongside systemic drugs |
| 4 | Beta-blockers (topical) | Reduce production but slower onset; adjunct use |
| 5 | Prostaglandin analogs | Too slow for acute emergency |
P DRUG SELECTION
| # | Drugs in CA Inhibitor Group | Reason to Select / Reject |
|---|---|---|
| 1 | Acetazolamide ✅ SELECTED | IV/oral; most used in acute glaucoma emergency; well-studied |
| 2 | Dorzolamide | Topical only; for open angle; not potent enough for acute attack |
| 3 | Brinzolamide | Topical only; adjunct therapy |
| 4 | Mannitol (adjunct) | IV osmotic; use if IOP not controlled by acetazolamide |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Carbonic Anhydrase Inhibitors + Miotic (Pilocarpine) |
| P Drug | Acetazolamide (systemic) + Pilocarpine 2% (topical) |
| Drug (Mechanism) | Acetazolamide: inhibits carbonic anhydrase in ciliary epithelium → reduces aqueous humor production → lowers IOP. Pilocarpine: M3 muscarinic agonist → pupillary constriction → pulls iris away from drainage angle → opens trabecular meshwork |
| Efficacy | Combination rapidly reduces IOP; acetazolamide acts within 30 min; pilocarpine opens blocked angle mechanically; definitive treatment is laser iridotomy |
| Safety | Acetazolamide ADRs: Metabolic acidosis, hypokalemia, paresthesia, sulfonamide hypersensitivity, renal stones, malaise. Pilocarpine ADRs: Spasm of accommodation (blurred vision), brow ache, miosis causing dim vision, retinal detachment (rare in high myopia) |
| Suitability | Emergency use only; once IOP controlled, laser peripheral iridotomy is the cure; Acetazolamide contraindicated in sulfa allergy, severe hepatic/renal disease |
| Cost | Both cheap and widely available |
| Dose & Frequency | Acetazolamide: 500 mg IV stat, then 250 mg orally QID. Pilocarpine 2% eye drops - 1 drop every 15 min × 4 doses, then every 6 hrs |
5. OPEN ANGLE GLAUCOMA
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Prostaglandin Analogs (topical) ✅ SELECTED | Most effective IOP reduction (25-35%); once daily; best compliance |
| 2 | Beta-blockers (topical) - Timolol | Effective, cheap; but systemic absorption causes bradycardia, bronchospasm |
| 3 | Alpha-2 agonists (Brimonidine) | Effective adjunct; systemic side effects (drowsiness, dry mouth) |
| 4 | Carbonic anhydrase inhibitors (topical) | Adjunct; less potent than PGAs |
| 5 | Miotics (Pilocarpine) | Effective but intolerable side effects (accommodative spasm, brow ache); 4x/day dosing |
P DRUG SELECTION
| # | Drugs in Prostaglandin Analog Group | Reason to Select / Reject |
|---|---|---|
| 1 | Latanoprost ✅ SELECTED | First PGA; most evidence; cheap generic available; gold standard |
| 2 | Bimatoprost | Slightly more effective; used in eyelash growth products; expensive |
| 3 | Travoprost | Similar efficacy to latanoprost |
| 4 | Tafluprost | Preservative-free; for patients with preservative allergy |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Prostaglandin Analogs (FP receptor agonists) |
| P Drug | Latanoprost |
| Drug (Mechanism) | FP prostanoid receptor agonist → increases uveoscleral outflow (unconventional pathway) → reduces IOP; does NOT affect aqueous humor production |
| Efficacy | Reduces IOP by 25-35%; most effective single topical agent; once-nightly dosing improves compliance; additive with beta-blockers and CA inhibitors |
| Safety | Adverse Reactions: Iris pigmentation (permanent, due to melanin increase), periorbital skin darkening, eyelash hypertrichosis (lengthening and darkening), conjunctival hyperemia; rarely - cystoid macular edema, uveitis |
| Suitability | First-line for POAG; once daily at bedtime; avoid in uveitic glaucoma; caution in aphakic/pseudophakic eyes (CME risk) |
| Cost | Moderately priced; generic available |
| Dose & Frequency | Latanoprost 0.005% - 1 drop OD at bedtime |
6. ANAPHYLACTIC SHOCK
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Sympathomimetic Amines (Catecholamines) ✅ SELECTED | Only class that is truly life-saving; physiologic antagonist; acts on all mediators simultaneously |
| 2 | Corticosteroids (Hydrocortisone) | Delayed onset (4-6 hrs); adjunct only; cannot replace epinephrine |
| 3 | Antihistaminics (Chlorpheniramine) | Block only H1 effects; do not reverse bronchospasm or hypotension; adjunct only |
| 4 | Bronchodilators (Salbutamol) | For bronchospasm component only; not for systemic anaphylaxis |
| 5 | IV fluids | Supportive; not primary treatment |
P DRUG SELECTION
| # | Drugs in Sympathomimetic Group | Reason to Select / Reject |
|---|---|---|
| 1 | Adrenaline (Epinephrine) ✅ SELECTED | Acts on α1 + β1 + β2; reverses ALL features of anaphylaxis simultaneously; NO alternative |
| 2 | Noradrenaline | Lacks β2 action; would worsen bronchospasm; NOT suitable |
| 3 | Dopamine | Primarily renal/cardiac doses; NOT appropriate for anaphylaxis |
| 4 | Phenylephrine | Only α1; no bronchodilation; NOT suitable |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Sympathomimetic Amines / Catecholamines |
| P Drug | Adrenaline (Epinephrine) |
| Drug (Mechanism) | α1: vasoconstriction → reverses hypotension, reduces angioedema. β1: positive inotrope/chronotrope → increases cardiac output. β2: bronchodilation → relieves bronchospasm. Also inhibits mast cell degranulation |
| Efficacy | The ONLY life-saving drug; reverses hypotension, bronchospasm, urticaria, and angioedema within minutes; no other drug can replace it in anaphylaxis |
| Safety | Adverse Reactions: Palpitations, tachycardia, ventricular arrhythmias, hypertensive crisis, anxiety, tremor, headache, pulmonary edema (with IV overdose). Note: In anaphylaxis, benefits ALWAYS outweigh risks - there are NO absolute contraindications |
| Suitability | IM route in anterolateral thigh (vastus lateralis) is preferred; faster absorption than SC; IV only in cardiac arrest. Suitable for ALL ages including children and pregnant women |
| Cost | Very cheap; available in all emergency settings |
| Dose & Frequency | 0.5 mg IM (0.5 mL of 1:1000 solution) in anterolateral thigh; repeat every 5-15 min as needed. Children: 0.01 mg/kg IM |
7. UNCOMPLICATED FALCIPARUM MALARIA
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Artemisinin-based Combination Therapy (ACT) ✅ SELECTED | WHO & NVBDCP first-line; effective against resistant strains; prevents resistance development |
| 2 | Chloroquine | Drug of choice for sensitive Pf malaria; BUT widespread resistance limits use for falciparum |
| 3 | Atovaquone-Proguanil | Effective; expensive; mainly for travelers/prophylaxis |
| 4 | Quinine | Second-line; reserved for severe/complicated malaria; many side effects (cinchonism) |
| 5 | Mefloquine | Effective but neuropsychiatric side effects; resistance in SE Asia |
P DRUG SELECTION
| # | Drugs in ACT Group | Reason to Select / Reject |
|---|---|---|
| 1 | Artemether + Lumefantrine ✅ SELECTED | WHO preferred; >95% cure rate; good tolerability; widely available (Coartem) |
| 2 | Artesunate + Amodiaquine | WHO alternative ACT; higher risk of agranulocytosis with amodiaquine |
| 3 | Artesunate + Mefloquine | Used in SE Asia; mefloquine neuropsychiatric effects limit use |
| 4 | Artesunate + SP (Sulfadoxine-Pyrimethamine) | NVBDCP regimen in India; resistance to SP growing |
| 5 | Dihydroartemisinin + Piperaquine | Alternative ACT; once daily; used in some countries |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Artemisinin-based Combination Therapy (ACT) |
| P Drug | Artemether + Lumefantrine (Coartem) |
| Drug (Mechanism) | Artemether: rapidly cleaved to dihydroartemisinin; generates free radicals that damage parasite proteins and membranes; acts on all asexual stages. Lumefantrine: partner drug; inhibits heme detoxification; long half-life prevents recrudescence and reduces resistance selection |
| Efficacy | >95% cure rate for uncomplicated P. falciparum including chloroquine-resistant strains; reduces gametocyte carriage |
| Safety | Adverse Reactions: Nausea, vomiting, dizziness, headache, palpitations, mild QTc prolongation; well tolerated overall. Avoid in 1st trimester of pregnancy (use quinine + clindamycin instead) |
| Suitability | Oral formulation; take with fatty food (increases lumefantrine absorption 16x); for adults and children >5 kg; not for severe malaria (use IV artesunate) |
| Cost | Moderately priced; available free through NVBDCP in India |
| Dose & Frequency | Adults (>35 kg): 4 tablets (each: Artemether 20mg + Lumefantrine 120mg) at 0, 8, 24, 36, 48, 60 hours (total 6 doses over 3 days) |
8. SHIGELLOSIS (ACUTE BACTERIAL DYSENTERY)
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Fluoroquinolones ✅ SELECTED | Bactericidal against Shigella; good tissue penetration; short course effective |
| 2 | Azithromycin | Alternative for fluoroquinolone-resistant Shigella; preferred in children |
| 3 | Co-trimoxazole | Widely resistant Shigella strains; no longer first-line in most areas |
| 4 | Ampicillin | High resistance rates; not reliable |
| 5 | Ceftriaxone | IV route; reserved for severe/resistant cases |
P DRUG SELECTION
| # | Drugs in Fluoroquinolone Group | Reason to Select / Reject |
|---|---|---|
| 1 | Ciprofloxacin ✅ SELECTED | Most used fluoroquinolone for GI infections; oral; well-studied in shigellosis |
| 2 | Norfloxacin | Good for GI infections; lower systemic bioavailability |
| 3 | Ofloxacin | Equally effective; alternative |
| 4 | Levofloxacin | Broader spectrum; reserved for respiratory infections usually |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Fluoroquinolones |
| P Drug | Ciprofloxacin |
| Drug (Mechanism) | Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV → prevents DNA replication, transcription, and repair → bactericidal |
| Efficacy | Shortens illness duration by 2-3 days; reduces fecal shedding; highly effective against Shigella sonnei and flexneri; short course (3-5 days) sufficient |
| Safety | Adverse Reactions: GI disturbance (nausea, diarrhea), headache, dizziness, photosensitivity, QTc prolongation, tendinopathy/tendon rupture (especially Achilles), peripheral neuropathy; Avoid in children <12 yrs (cartilage damage), pregnancy, epilepsy |
| Suitability | Oral; ORS must accompany treatment; avoid antidiarrheals (loperamide) in bloody dysentery |
| Cost | Very cheap as generic; widely available |
| Dose & Frequency | 500 mg BD (twice daily) for 3-5 days |
9. TYPHOID FEVER
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Fluoroquinolones ✅ SELECTED | Bactericidal; excellent intracellular penetration (where Salmonella resides in macrophages); short course |
| 2 | Azithromycin | WHO recommended for uncomplicated typhoid; preferred in children and MDR cases |
| 3 | Third-generation cephalosporins (Ceftriaxone) | IV; for severe/complicated typhoid or quinolone-resistant strains |
| 4 | Chloramphenicol | Historically first-line; high resistance; bone marrow toxicity; obsolete |
| 5 | Co-trimoxazole | Significant resistance; backup only |
P DRUG SELECTION
| # | Drugs in Fluoroquinolone Group | Reason to Select / Reject |
|---|---|---|
| 1 | Ciprofloxacin ✅ SELECTED | First-line for susceptible Salmonella typhi; oral; well-studied |
| 2 | Ofloxacin | Equally effective alternative |
| 3 | Levofloxacin | Option for quinolone-resistant strains at higher doses |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Fluoroquinolones |
| P Drug | Ciprofloxacin |
| Drug (Mechanism) | Inhibits DNA gyrase and topoisomerase IV; bactericidal; achieves high intracellular concentrations in macrophages where Salmonella typhi resides and multiplies |
| Efficacy | Defervescence in 3-5 days; bacteriological clearance; low relapse rate; shorter course than chloramphenicol |
| Safety | Adverse Reactions: Same as in shigellosis - GI upset, headache, photosensitivity, QTc prolongation, tendon rupture, peripheral neuropathy. Avoid in children, pregnancy |
| Suitability | Oral route; 7-10 days for typhoid (longer than dysentery); not suitable in quinolone-resistant typhoid (increasing in India) |
| Cost | Very cheap |
| Dose & Frequency | 500 mg BD for 7-10 days |
10. PULMONARY EDEMA DUE TO LEFT-SIDED CHF
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Loop Diuretics ✅ SELECTED | Most potent diuretics; IV route; dual mechanism (early venodilation + diuresis); drug of choice for acute pulmonary edema |
| 2 | Morphine | Previously used; reduces anxiety, venodilates; now controversial due to respiratory depression risk |
| 3 | IV Nitrates (Nitroglycerine) | Useful venodilator; adjunct to furosemide in acute setting |
| 4 | Thiazide diuretics | Less potent; oral only; not suitable for acute emergency |
| 5 | ACE inhibitors | Long-term CHF management; not acute emergency drugs |
P DRUG SELECTION
| # | Drugs in Loop Diuretic Group | Reason to Select / Reject |
|---|---|---|
| 1 | Furosemide (Frusemide) ✅ SELECTED | Most widely used loop diuretic; IV form available; best studied in pulmonary edema |
| 2 | Torsemide | Better oral bioavailability; longer acting; but less IV data |
| 3 | Bumetanide | Equally potent; 1 mg = 40 mg furosemide; alternative |
| 4 | Ethacrynic acid | Only loop diuretic without sulfa group; reserved for sulfa allergy |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Loop Diuretics |
| P Drug | Furosemide (Frusemide) |
| Drug (Mechanism) | Inhibits Na+/K+/2Cl- cotransporter (NKCC2) in thick ascending limb of Loop of Henle → massive natriuresis and diuresis. Early effect (within 5 min IV): venodilation via prostaglandin release → reduces preload before diuresis starts |
| Efficacy | Most powerful diuretic; dramatically reduces pulmonary venous congestion; relieves dyspnea rapidly; IV onset within 5 min; diuresis in 30 min |
| Safety | Adverse Reactions: Hypokalemia (most important), hyponatremia, hypomagnesemia, hypocalcemia, hyperuricemia (precipitates gout), hyperglycemia, metabolic alkalosis, ototoxicity (high IV doses - dose-related, usually reversible), dehydration, postural hypotension; Contraindicated in anuria |
| Suitability | IV route in acute setting; monitor urine output, electrolytes, creatinine; replace potassium; suitable for all adults with normal or high urine output |
| Cost | Extremely cheap; universally available |
| Dose & Frequency | Acute: 40 mg IV slow (over 2 min); repeat with 80 mg IV if no response in 30 min. Maintenance: 20-80 mg OD orally |
11. HYPERTENSION IN PREGNANT WOMAN (PREECLAMPSIA)
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Centrally Acting Alpha-2 Agonists ✅ SELECTED | Methyldopa - proven safety in all trimesters; most studied drug in obstetric hypertension |
| 2 | Calcium Channel Blockers (Nifedipine) | Alternative for chronic HTN in pregnancy; also used for acute severe HTN |
| 3 | Beta-blockers (Labetalol) | Used for acute management; oral labetalol is second-line for chronic HTN in pregnancy |
| 4 | ACE inhibitors / ARBs | ABSOLUTELY CONTRAINDICATED in pregnancy (teratogenic - renal agenesis, oligohydramnios) |
| 5 | Thiazide diuretics | Avoid in pregnancy; reduce plasma volume, worsen uteroplacental perfusion |
P DRUG SELECTION
| # | Drugs in Alpha-2 Agonist Group / Safe in Pregnancy | Reason to Select / Reject |
|---|---|---|
| 1 | Methyldopa ✅ SELECTED | Most studied; proven fetal safety over decades; WHO recommended for chronic HTN in pregnancy |
| 2 | Clonidine | Also alpha-2 agonist; less data in pregnancy; risk of rebound hypertension |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Centrally Acting Alpha-2 Agonists |
| P Drug | Methyldopa |
| Drug (Mechanism) | Prodrug → converted to α-methyl-norepinephrine in CNS → activates central α2 receptors → reduces sympathetic outflow → decreases peripheral vascular resistance and cardiac output → lowers BP |
| Efficacy | Effective antihypertensive; maintains uteroplacental blood flow; no adverse fetal effects shown in long-term follow-up studies; first-line for CHRONIC HTN in pregnancy |
| Safety | Adverse Reactions: Sedation (most common), dry mouth, postural hypotension, bradycardia, hemolytic anemia (Coombs positive - 20% patients), hepatitis/hepatotoxicity (rare but serious), depression, rebound hypertension on sudden withdrawal; SAFE for fetus (Category B) |
| Suitability | Drug of CHOICE for chronic HTN in pregnancy; for acute severe HTN (BP >160/110 mmHg) in preeclampsia - use IV Labetalol or IV Hydralazine |
| Cost | Cheap, widely available |
| Dose & Frequency | 250 mg BD-TDS initially; maintenance 500 mg - 2g/day in 2-4 divided doses |
12. STABLE ANGINA
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Beta-Adrenergic Blockers ✅ SELECTED | Reduce myocardial O2 demand; also reduce mortality post-MI; no tolerance; most evidence |
| 2 | Nitrates (Long-acting - Isosorbide dinitrate) | Effective antianginal; but tolerance develops with regular use; no mortality benefit |
| 3 | Calcium Channel Blockers (Amlodipine) | Good for vasospastic + stable angina; first-line when beta-blockers contraindicated |
| 4 | Ranolazine | Second-line; inhibits late Na+ current; for refractory angina |
| 5 | Ivabradine | Pure heart rate reduction; second-line or add-on |
P DRUG SELECTION
| # | Drugs in Beta-Blocker Group | Reason to Select / Reject |
|---|---|---|
| 1 | Atenolol ✅ SELECTED | Cardioselective β1 blocker; OD dosing; no CNS side effects; well tolerated |
| 2 | Metoprolol | Also cardioselective; BD dosing; equally effective |
| 3 | Propranolol | Non-selective; causes bronchospasm; more side effects; avoid in asthma |
| 4 | Bisoprolol | Most cardioselective; preferred in patients with mild COPD |
| 5 | Carvedilol | Alpha + beta blocker; preferred in heart failure with angina |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Beta-Adrenergic Blockers (Beta-1 selective) |
| P Drug | Atenolol |
| Drug (Mechanism) | Selective β1 adrenergic receptor blocker → reduces heart rate, myocardial contractility, and cardiac output → decreases myocardial O2 demand; increases diastolic filling time → improves subendocardial perfusion |
| Efficacy | Prevents exercise-induced angina; reduces angina frequency; reduces mortality post-MI; no tolerance unlike nitrates |
| Safety | Adverse Reactions: Bradycardia, heart block, cold extremities, fatigue, depression, erectile dysfunction, masks hypoglycemic symptoms in diabetics, rebound angina/MI on abrupt withdrawal. Contraindicated: Asthma/COPD, bradycardia <50/min, AV block (2nd/3rd degree), decompensated heart failure, Prinzmetal (vasospastic) angina |
| Suitability | First-line for stable angina; especially preferred with co-existing hypertension, post-MI, tachycardia; once daily dosing; taper gradually on stopping |
| Cost | Very cheap; widely available |
| Dose & Frequency | 25-100 mg OD (once daily) |
13. PARKINSONISM
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Dopamine Precursor + Decarboxylase Inhibitor ✅ SELECTED | Levodopa + Carbidopa = most effective symptomatic treatment; gold standard |
| 2 | Dopamine Agonists (Pramipexole, Ropinirole) | Preferred in young patients (<60 yrs) to delay levodopa; less effective than levodopa |
| 3 | MAO-B Inhibitors (Selegiline, Rasagiline) | Mild symptomatic benefit; neuroprotective?; adjunct use |
| 4 | COMT Inhibitors (Entacapone) | Used to extend levodopa effect; not monotherapy |
| 5 | Anticholinergics (Benzhexol/Trihexyphenidyl) | Only for tremor-dominant young patients; not effective for bradykinesia/rigidity |
| 6 | Amantadine | Mild benefit; antidyskinesia effect useful; not potent enough as monotherapy |
P DRUG SELECTION
| # | Drugs in Dopamine Precursor Group | Reason to Select / Reject |
|---|---|---|
| 1 | Levodopa + Carbidopa ✅ SELECTED | Most effective combination; standard of care; reduces peripheral conversion of levodopa → more drug to brain, fewer peripheral side effects |
| 2 | Levodopa alone (without DCI) | Much higher doses needed; more peripheral side effects; obsolete |
| 3 | Levodopa + Benserazide (Madopar) | Equally effective alternative combination |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Dopamine Precursor + Peripheral Decarboxylase Inhibitor (DCI) |
| P Drug | Levodopa + Carbidopa (Syndopa, Sinemet) |
| Drug (Mechanism) | Levodopa crosses BBB → converted to dopamine by DOPA decarboxylase in striatum → replenishes depleted dopamine → restores dopamine-acetylcholine balance. Carbidopa: peripheral DOPA decarboxylase inhibitor → prevents peripheral levodopa conversion → reduces peripheral side effects and increases CNS bioavailability by 75% |
| Efficacy | Most effective drug for all cardinal features (tremor, rigidity, bradykinesia, postural instability); dramatically improves quality of life; gold standard for PD motor symptoms |
| Safety | Adverse Reactions: Nausea, vomiting (early), postural hypotension, cardiac arrhythmias. Long-term (>5 yrs): Wearing-off phenomenon, on-off fluctuations, dyskinesias (peak-dose), hallucinations, psychosis, impulse control disorders; Avoid in narrow-angle glaucoma, psychosis |
| Suitability | Best for elderly (>60 yrs) with significant functional impairment; in younger patients, delay levodopa - use dopamine agonists first; dose titration required |
| Cost | Moderately priced; generic widely available |
| Dose & Frequency | Carbidopa 25 mg + Levodopa 100 mg (1 tablet) TDS initially with meals; titrate up every 2-4 weeks; usual maintenance up to 4-8 tablets/day |
14. OSTEOPOROSIS
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Bisphosphonates ✅ SELECTED | Antiresorptive; best evidence for fracture reduction; first-line per all guidelines |
| 2 | SERMs (Raloxifene) | Only vertebral fracture prevention; no hip fracture benefit; DVT risk |
| 3 | Teriparatide (PTH analog) | Anabolic; most effective but expensive; injectable; only 2-yr course |
| 4 | Denosumab (anti-RANK-L) | Highly effective; injectable every 6 months; expensive; rebound if stopped |
| 5 | Hormone Replacement Therapy (Estrogen) | Effective but breast cancer, DVT risks; not first-line |
| 6 | Calcium + Vitamin D alone | Supplementation only; not sufficient as monotherapy for osteoporosis |
P DRUG SELECTION
| # | Drugs in Bisphosphonate Group | Reason to Select / Reject |
|---|---|---|
| 1 | Alendronate ✅ SELECTED | Most evidence base; oral weekly dosing; reduces vertebral AND hip fractures; generic available |
| 2 | Risedronate | Similar efficacy; weekly or monthly; alternative |
| 3 | Ibandronate | Monthly oral or quarterly IV; no proven hip fracture benefit |
| 4 | Zoledronate | Annual IV infusion; most potent; for patients unable to take oral bisphosphonates |
| 5 | Etidronate | Oldest bisphosphonate; first generation; less potent; rarely used now |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Bisphosphonates (Anti-resorptive agents) |
| P Drug | Alendronate (Alendronic acid) |
| Drug (Mechanism) | Nitrogen-containing bisphosphonate → absorbed into bone matrix → taken up by osteoclasts → inhibits farnesyl pyrophosphate synthase (mevalonate pathway) → osteoclast apoptosis → reduced bone resorption → increased bone mineral density |
| Efficacy | Reduces vertebral fracture risk by 50%, hip fracture risk by 47%; increases BMD at spine and hip; most studied bisphosphonate |
| Safety | Adverse Reactions: Esophageal irritation/ulceration (most important oral ADR), GERD, abdominal pain; Osteonecrosis of the jaw (ONJ - rare, with prolonged use); Atypical femoral fractures (with >5 yrs use); Atrial fibrillation (rare); Hypocalcemia. Strict administration rules required |
| Suitability | First-line for postmenopausal osteoporosis and glucocorticoid-induced osteoporosis; weekly dosing improves compliance; MUST give with calcium 1000-1200 mg/day + Vit D 800 IU/day |
| Cost | Cheap; weekly generic widely available |
| Dose & Frequency | 70 mg orally ONCE WEEKLY - Take first thing in morning, fasting, with full glass plain water, sit/stand upright for 30 min, eat nothing for 30 min |
15. OSTEOARTHRITIS OF BOTH KNEES
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Simple Analgesics (Non-opioid) ✅ SELECTED | Paracetamol - safest first-line analgesic per ACR/EULAR guidelines; no GI/CV/renal risks |
| 2 | NSAIDs (Ibuprofen, Diclofenac) | More effective for inflammation; but GI, cardiovascular, renal risks especially in elderly |
| 3 | Topical NSAIDs (Diclofenac gel) | Good for localized joint pain; fewer systemic effects; alternative first-line |
| 4 | Opioids | For severe refractory pain only; dependence risk; not first-line |
| 5 | Intra-articular corticosteroids | For acute flare-ups; not regular treatment |
| 6 | Duloxetine (SNRI) | For central sensitization pain in OA; adjunct |
P DRUG SELECTION
| # | Drugs in Simple Analgesic Group | Reason to Select / Reject |
|---|---|---|
| 1 | Paracetamol (Acetaminophen) ✅ SELECTED | Safest; suitable for elderly; no GI ulceration; well tolerated; first-line |
| 2 | Tramadol (weak opioid) | Moderate-severe OA pain; dependence risk; only if paracetamol insufficient |
| 3 | Codeine | Opioid; not first-line; constipation, dependence |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Simple Analgesics (Non-opioid, Non-NSAID) |
| P Drug | Paracetamol (Acetaminophen) |
| Drug (Mechanism) | Inhibits COX enzymes in CNS (central mechanism); activates descending serotonergic pain pathways; possibly acts on cannabinoid system (AM404 metabolite); Analgesic and antipyretic - NO peripheral anti-inflammatory action |
| Efficacy | Effective for mild-moderate OA pain; reduces pain and improves function; first-line per ACR 2019 and EULAR OA guidelines; effect size modest but safety profile unmatched |
| Safety | Adverse Reactions: SAFEST analgesic - no GI ulceration, no platelet inhibition, no renal prostaglandin inhibition. Main risk: Hepatotoxicity in overdose (>7.5-10 g acute) via NAPQI metabolite - can cause fulminant hepatic failure; risk increased with alcohol, fasting, hepatic disease; fixed drug eruption (rare rash) |
| Suitability | Drug of CHOICE for OA in elderly, peptic ulcer patients, renal impairment, cardiac disease, anticoagulant therapy; safe in all age groups; scheduled dosing (not PRN) more effective |
| Cost | Extremely cheap; universally available |
| Dose & Frequency | 500 mg - 1g TDS to QID (three to four times daily); maximum 4g/day; with food if GI upset |
16. ACUTE GOUTY ARTHRITIS
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | NSAIDs ✅ SELECTED | Most effective for acute gout; rapid anti-inflammatory; first-line for uncomplicated acute attack |
| 2 | Colchicine | Highly effective; specifically inhibits microtubule assembly and neutrophil migration; preferred alternative when NSAIDs contraindicated |
| 3 | Corticosteroids (Oral Prednisolone / Intra-articular) | When both NSAIDs and colchicine are contraindicated; equally effective |
| 4 | IL-1 inhibitors (Anakinra, Canakinumab) | Biologics for refractory gout; expensive; not routine |
| 5 | Urate-lowering drugs (Allopurinol) | NOT for acute attack - may prolong/worsen acute attack; for chronic prophylaxis only |
P DRUG SELECTION
| # | Drugs in NSAID Group (for Gout) | Reason to Select / Reject |
|---|---|---|
| 1 | Indomethacin ✅ SELECTED | Most potent NSAID; additional mechanism of inhibiting urate crystal phagocytosis; historical drug of choice for gout |
| 2 | Naproxen | Also effective; better GI profile than indomethacin; modern alternative |
| 3 | Etoricoxib | COX-2 selective; less GI risk; effective in acute gout; good option in elderly |
| 4 | Diclofenac | Effective; available widely |
| 5 | Ibuprofen | Less potent for acute gout; not ideal |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | NSAIDs (Non-selective COX inhibitors) |
| P Drug | Indomethacin |
| Drug (Mechanism) | Potent non-selective COX-1 and COX-2 inhibitor → reduces prostaglandin synthesis; ALSO inhibits urate crystal phagocytosis by neutrophils and blocks neutrophil migration into the joint → dual anti-inflammatory mechanism in gout |
| Efficacy | Most effective NSAID for acute gout; pain relief begins within hours; swelling and redness reduce within 24-48 hrs |
| Safety | Adverse Reactions: GI irritation, peptic ulceration, GI bleeding (highest GI risk among NSAIDs), headache, dizziness, confusion (especially elderly), fluid retention, edema, hypertension, hyperkalemia, acute kidney injury, platelet inhibition; Avoid in peptic ulcer, renal failure, elderly, anticoagulant users |
| Suitability | Short course (5-7 days) only; take with food; combine with PPI (omeprazole 20 mg OD) for GI protection; Do NOT start allopurinol during acute attack |
| Cost | Very cheap; widely available |
| Dose & Frequency | 50 mg TDS (three times daily) for 2-3 days, then taper to 25 mg TDS for 3-4 more days; or 75 mg SR BD for 5-7 days |
17. RHEUMATOID ARTHRITIS
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | DMARDs (Conventional Synthetic) ✅ SELECTED | Methotrexate - anchor DMARD; slows erosion; modifies disease; best evidence; cost-effective |
| 2 | Biological DMARDs (Anti-TNF - Adalimumab, Etanercept) | More effective; for MTX-refractory cases; very expensive; infection risk |
| 3 | JAK Inhibitors (Tofacitinib, Baricitinib) | Oral biologics; for failure of conventional DMARDs; expensive |
| 4 | NSAIDs | For symptom relief only; do NOT modify disease or prevent erosions |
| 5 | Corticosteroids | Bridge therapy; for disease flares; not long-term monotherapy |
| 6 | Hydroxychloroquine, Sulfasalazine | Milder DMARDs; often combined with MTX in triple therapy |
P DRUG SELECTION
| # | Drugs in Conventional DMARD Group | Reason to Select / Reject |
|---|---|---|
| 1 | Methotrexate (MTX) ✅ SELECTED | Anchor drug; most widely used; weekly dosing; best long-term evidence; cheap |
| 2 | Hydroxychloroquine (HCQ) | Mild DMARD; for early/mild RA; combined with MTX in triple therapy |
| 3 | Sulfasalazine | Moderate DMARD; alternative; combined with MTX |
| 4 | Leflunomide | Similar efficacy to MTX; daily oral; liver toxicity; alternative when MTX intolerant |
| 5 | Azathioprine | Immunosuppressive; less commonly used; more side effects |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Conventional Synthetic DMARDs (Disease Modifying Anti-Rheumatic Drugs) |
| P Drug | Methotrexate (MTX) |
| Drug (Mechanism) | Folate antagonist → inhibits dihydrofolate reductase (DHFR) → reduces purine synthesis → inhibits lymphocyte proliferation and pro-inflammatory cytokine production (IL-1, IL-6, TNF-α); also increases extracellular adenosine (anti-inflammatory) |
| Efficacy | Gold standard / anchor DMARD for RA; reduces swollen joint count, tender joint count, ESR/CRP; slows radiological erosion progression; improves functional score; most widely used DMARD worldwide |
| Safety | Adverse Reactions: Nausea, vomiting, mucositis/oral ulcers (most common); Hepatotoxicity - elevated LFTs, cirrhosis (with long-term cumulative dose); Bone marrow suppression - pancytopenia; MTX pneumonitis (interstitial lung disease - most serious acute complication); Teratogenicity (Category X - causes abortions, fetal malformations); Alopecia; Renal toxicity. Folic acid 5 mg/day (on non-MTX days) MUST be given to reduce mucositis/hepatotoxicity |
| Suitability | Weekly dosing (not daily); must avoid alcohol (hepatotoxicity); requires regular monitoring - LFT, CBC, creatinine every 4-8 weeks; effective contraception mandatory (both sexes); stop 3 months before planned pregnancy |
| Cost | Very cheap; generic widely available |
| Dose & Frequency | 7.5-25 mg ONCE WEEKLY orally; start at 7.5-10 mg/week; increase by 2.5 mg every 4-6 weeks based on response and tolerance |
18. TYPE 2 DIABETES MELLITUS (Maturity Onset Diabetes)
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Biguanides ✅ SELECTED | Metformin - first-line per ADA, IDF, WHO; no hypoglycemia; cardioprotective; cheapest |
| 2 | Sulfonylureas (Glipizide, Gliclazide) | Effective but causes hypoglycemia; weight gain; second-line |
| 3 | DPP-4 inhibitors (Sitagliptin) | Well tolerated; no hypoglycemia; weight neutral; but expensive |
| 4 | SGLT-2 inhibitors (Empagliflozin) | Cardioprotective + renoprotective; added after metformin in CV risk patients |
| 5 | GLP-1 agonists (Liraglutide) | Weight loss + CV benefit; injectable; expensive |
| 6 | Thiazolidinediones (Pioglitazone) | Insulin sensitizer; weight gain, fluid retention, fracture risk |
| 7 | Insulin | Required when oral agents fail or in ketosis-prone DM |
P DRUG SELECTION
| # | Drugs in Biguanide Group | Reason to Select / Reject |
|---|---|---|
| 1 | Metformin ✅ SELECTED | The ONLY biguanide in clinical use; phenformin and buformin withdrawn due to severe lactic acidosis; metformin has excellent safety record |
| 2 | Phenformin | Withdrawn from market; high lactic acidosis risk |
| 3 | Buformin | Withdrawn from market |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Biguanides |
| P Drug | Metformin |
| Drug (Mechanism) | Activates AMP-activated protein kinase (AMPK) via inhibition of mitochondrial complex I → primarily reduces hepatic gluconeogenesis (main mechanism); secondarily improves peripheral insulin sensitivity in muscle and fat; decreases intestinal glucose absorption; does NOT stimulate insulin secretion → NO hypoglycemia |
| Efficacy | Reduces HbA1c by 1-2%; first-line per all guidelines (ADA 2024, IDF, NICE); cardiovascular protective effect (UKPDS trial showed reduced MI, mortality); weight neutral or causes mild weight loss; reduces diabetes progression in prediabetes |
| Safety | Adverse Reactions: GI side effects - nausea, vomiting, diarrhea, metallic taste, abdominal cramps (most common, dose-dependent, take with food, use XR formulation); Lactic acidosis (most serious but rare - incidence 0.03/1000 patient-years; occurs in overdose or when contraindications are ignored); Vitamin B12 deficiency with long-term use; No hypoglycemia (major safety advantage). Contraindications: eGFR <30 (accumulation → lactic acidosis), severe hepatic disease, alcoholism, acute illness, IV contrast (withhold 48 hrs before and after) |
| Suitability | Drug of CHOICE for T2DM - especially overweight/obese; suitable for most patients; take with meals to minimize GI effects; use extended release (XR) for better GI tolerability |
| Cost | Extremely cheap; most widely used oral antidiabetic worldwide |
| Dose & Frequency | 500 mg OD-BD with meals initially; titrate every 2 weeks; target 1000 mg BD (maintenance); maximum 2500 mg/day. XR: 500-2000 mg OD with evening meal |
MASTER QUICK REFERENCE TABLE
| # | Condition | P Group Selected | P Drug Selected | Dose & Frequency |
|---|---|---|---|---|
| 1 | Vertigo | Antihistaminics | Cinnarizine | 25 mg TDS |
| 2 | Mild Migraine | NSAIDs | Aspirin | 600-900 mg stat, repeat 4-6 hrly |
| 3 | Severe Migraine | Triptans (5-HT1B/D agonists) | Sumatriptan | 50-100 mg oral stat; max 300 mg/day |
| 4 | Acute Congestive Glaucoma | CA Inhibitor + Miotic | Acetazolamide + Pilocarpine 2% | 500 mg IV + 1 drop q15 min × 4 |
| 5 | Open Angle Glaucoma | Prostaglandin Analogs | Latanoprost 0.005% | 1 drop OD at bedtime |
| 6 | Anaphylactic Shock | Catecholamines | Adrenaline 1:1000 | 0.5 mg IM, repeat q5-15 min |
| 7 | Uncomplicated Falciparum Malaria | ACT | Artemether + Lumefantrine | 4 tabs at 0,8,24,36,48,60 hrs |
| 8 | Shigellosis | Fluoroquinolones | Ciprofloxacin | 500 mg BD × 3-5 days |
| 9 | Typhoid Fever | Fluoroquinolones | Ciprofloxacin | 500 mg BD × 7-10 days |
| 10 | Pulmonary Edema / CHF | Loop Diuretics | Furosemide | 40-80 mg IV stat |
| 11 | HTN in Pregnancy | Alpha-2 Agonists | Methyldopa | 250 mg BD-TDS |
| 12 | Stable Angina | Beta-1 Blockers | Atenolol | 25-100 mg OD |
| 13 | Parkinsonism | Dopamine Precursor + DCI | Levodopa + Carbidopa | 100/25 mg TDS (titrate up) |
| 14 | Osteoporosis | Bisphosphonates | Alendronate | 70 mg once weekly |
| 15 | Osteoarthritis | Simple Analgesics | Paracetamol | 500 mg-1g TDS-QID; max 4g/day |
| 16 | Acute Gout | NSAIDs | Indomethacin | 50 mg TDS × 5-7 days |
| 17 | Rheumatoid Arthritis | DMARDs | Methotrexate | 7.5-25 mg once weekly |
| 18 | Type 2 DM | Biguanides | Metformin | 500 mg OD initially; 1000 mg BD maintenance |
Exam Tip: Always explain WHY you selected the P group over others, and WHY you selected the P drug over other drugs in that group. The tables above give you exactly that justification. Best of luck tomorrow! 🎯
This is a shared conversation. Sign in to Orris to start your own chat.